Once-Daily Pill Could Double Survival Time for Pancreatic Cancer Patients, Landmark Trial Reveals
A groundbreaking drug called daraxonrasib has shown the ability to double survival time in advanced pancreatic cancer patients, with experts calling it a historic gamechanger.
Once-Daily Pill Offers New Hope Against the World's Deadliest Cancer
A clinical trial has produced what many oncology experts are describing as the most significant breakthrough in pancreatic cancer treatment in decades. A once-daily oral drug called daraxonrasib has demonstrated the ability to double survival time in patients diagnosed with advanced pancreatic cancer — a disease long considered one of medicine's most formidable challenges.
The findings, presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, have sent waves of optimism through the global medical community, with leading cancer specialists openly describing the results as a "gamechanger."
A Cancer With Few Good Options — Until Now
Pancreatic cancer has historically been one of the hardest cancers to treat effectively. Diagnoses are frequently delayed, with more than half of all cases only confirmed after the disease has already spread to other parts of the body. For years, treatment options have remained frustratingly limited, and survival rates have changed very little despite ongoing research efforts.
Chemotherapy, while still commonly used, offers modest benefits and often comes with a heavy burden of side effects. Against this bleak backdrop, the arrival of daraxonrasib represents a striking departure from the status quo.
What the Trial Found
The clinical trial enrolled 500 patients, all of whom had been diagnosed with pancreatic cancer that had already metastasized — meaning it had spread beyond the original site. Participants who received daraxonrasib survived for an average of 13.2 months, compared to just 6.6 to 6.7 months for those treated with standard chemotherapy. That represents roughly double the survival time.
Equally important, the drug was associated with fewer side effects than chemotherapy, a factor that significantly affects a patient's quality of life during treatment.
The trial was led by researchers at the Dana-Farber Cancer Institute in Boston, one of the world's most respected cancer research institutions.
Experts React With Rare Enthusiasm
The response from leading oncologists has been unusually emotional and unequivocal.
Dr. Rachna Shroff, Chief of Oncology at the University of Arizona Cancer Center and an ASCO expert in gastrointestinal cancers, admitted that reading the trial results moved her to tears.
"Having treated pancreatic cancer for 16 years, I actually started crying in clinic. This is such an incredibly impactful study for our patients."
She described the findings as "landscape-changing," adding that the medical community was witnessing "unprecedented survival" outcomes in a disease that had long resisted progress.
Dr. Julie Gralow, ASCO's Chief Medical Officer and Executive Vice President, went even further in her praise, calling the drug a "gamechanger" and elevating the analogy commonly used to describe it.
"I've heard this study described as a home run. I would actually say it's a grand slam."
How Daraxonrasib Works
The science behind daraxonrasib centers on a protein called Kras, which plays a central role in driving the growth of nearly all pancreatic cancers. Kras belongs to the broader Ras family of genes, which, when mutated, can send continuous signals to cancer cells instructing them to grow and divide — even when they should not.
More than 90% of patients with the most common form of pancreatic cancer — pancreatic ductal adenocarcinoma (mPDAC) — carry a mutation in the Kras gene, specifically a variant known as Ras G12. This mutation results in a hyperactive Kras protein that essentially keeps the cancer's growth engine running unchecked.
Daraxonrasib is classified as a Ras(On) multi-selective inhibitor — a new generation of targeted therapy. The drug works by binding molecules together in a way that effectively grabs and shuts down the Kras protein. Crucially, it can do this regardless of which specific Kras variant is present, making it broadly applicable across the pancreatic cancer patient population.
As one leading researcher summarized: "The Ras revolution is here, and this study is proof of principle that targeting Kras in pancreatic cancer is feasible and effective."
Patient Advocates Hail a Historic Moment
Organizations that support pancreatic cancer patients have responded to the news with cautious but genuine optimism.
Paula Hanford, Chief Executive of UK-based Pancreatic Cancer Action, described the trial results as among the most significant developments she had ever witnessed in her field.
"For far too long, people diagnosed with pancreatic cancer have had incredibly limited treatment options and survival rates that have remained devastatingly low. To see a trial showing the potential to nearly double survival time in advanced pancreatic cancer is hugely encouraging and gives real hope to patients and families facing this disease."
Anna Jewell, Director of Services, Research and Innovation at Pancreatic Cancer UK, echoed that sentiment, while also emphasizing the urgency of making new treatments accessible to those who need them most.
"Tragically, half of all people with pancreatic cancer die within just three months of their diagnosis. More time with those we love most is truly priceless. We must do everything possible to ensure the most promising new treatments are available."
A Gateway to Broader Cancer Breakthroughs?
Beyond pancreatic cancer, experts gathering in Chicago expressed hope that the success of daraxonrasib could signal a wider revolution in cancer treatment. Because Ras gene mutations are implicated in a range of other cancers, similar targeted therapies are already being investigated for lung cancer and colon cancer, potentially extending the benefits of this research far beyond a single diagnosis.
The path from clinical trial to widespread patient access still involves regulatory hurdles and further research, but the momentum generated by these results marks a turning point that the oncology world has been waiting years to reach.
